Spruce Biosciences (SPRB) Invested Capital (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Invested Capital for 4 consecutive years, with $42.5 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 39.66% to $42.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.5 million through Dec 2025, up 39.66% year-over-year, with the annual reading at $42.5 million for FY2025, 39.66% up from the prior year.
  • Invested Capital for Q4 2025 was $42.5 million at Spruce Biosciences, up from $5.9 million in the prior quarter.
  • The five-year high for Invested Capital was $109.6 million in Q1 2023, with the low at $5.9 million in Q3 2025.
  • Average Invested Capital over 4 years is $62.8 million, with a median of $69.2 million recorded in 2022.
  • Peak annual rise in Invested Capital hit 39.66% in 2025, while the deepest fall reached 88.88% in 2025.
  • Over 4 years, Invested Capital stood at $70.1 million in 2022, then rose by 11.44% to $78.1 million in 2023, then tumbled by 61.04% to $30.4 million in 2024, then soared by 39.66% to $42.5 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $42.5 million, $5.9 million, and $14.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.